Pfizer plans to pull leukemia drug Mylotarg from U.S. market

06/21/2010 | Reuters

Pfizer will voluntarily take Mylotarg off the U.S. market Oct. 15 after the injectable drug failed to show efficacy during a study when given in combination with chemotherapy to patients with acute myeloid leukemia. The decision follows the FDA's recommendation to withdraw the product because of safety concerns and lack of clinical benefit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX